These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

42 related articles for article (PubMed ID: 6108653)

  • 1. [Configuration frequency analysis. XI. Strategies of symptom configuration comparison before and after therapy].
    Lienert GA; Straube E
    Z Klin Psychol Psychother; 1980; 28(2):110-23. PubMed ID: 6108653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Schizophrenic thinking and neuroleptic dosage.
    Puente AE; Andersson C
    J Clin Psychol; 1987 Mar; 43(2):189-97. PubMed ID: 2883201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
    Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
    Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia.
    Wehmeier PM; Kluge M; Schneider E; Schacht A; Wagner T; Schreiber W
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):703-12. PubMed ID: 17289237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of the emotional blunting and its prognostic importance during neuroleptic treatment of schizophrenia].
    Kukulska D
    Psychiatr Pol; 2003; 37(6):999-1012. PubMed ID: 14727372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stabilization of the internal structure of persistent auditory verbal hallucinations in schizophrenia.
    Chang JS; Yi JS; Ahn YM; Kim JH; Kim YS
    Aust N Z J Psychiatry; 2009 Mar; 43(3):244-51. PubMed ID: 19221913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of 2 depression scales and their relationship with negative and akinetic symptoms in stabilized schizophrenic patients].
    Langlois-Thery S; Dollfus S; Lesieur P; Petit M
    Encephale; 1994; 20(5):487-93. PubMed ID: 7828511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive validity of proposed remission criteria in first-episode schizophrenic patients responding to antipsychotics.
    Wunderink L; Nienhuis FJ; Sytema S; Wiersma D
    Schizophr Bull; 2007 May; 33(3):792-6. PubMed ID: 16894026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials.
    Kinon BJ; Ascher-Svanum H; Adams DH; Chen L
    J Clin Psychopharmacol; 2008 Oct; 28(5):544-9. PubMed ID: 18794651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A four-dimensional model of chronic schizophrenia based on the factorial structure of the Positive and Negative Syndrome Scale (PANSS). A study of a group of 153 chronic schizophrenic patients and comparison with the factorial structure of the BPRS].
    Loas G; Noisette C; Legrand A; Delahousse J
    Encephale; 1997; 23(1):10-8. PubMed ID: 9172962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Algorithm for the treatment of negative symptoms in chronic schizophrenia.
    Tsutsumi T; Uchimura H
    Psychiatry Clin Neurosci; 1999 Oct; 53 Suppl():S15-7. PubMed ID: 10560892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Symptom change and extrapyramidal side effects during acute haloperidol treatment in chronic geriatric schizophrenics.
    Weisbard JJ; Pardo M; Pollack S
    Psychopharmacol Bull; 1997; 33(1):119-22. PubMed ID: 9133762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Incidence of the deficit form in refractory schizophrenia].
    Samuelian JC
    Encephale; 1996 Jun; 22 Spec No 2():19-23. PubMed ID: 8767037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Seroquel in a resistant schizophrenic with negative and positive symptoms].
    Reznik I; Benatov R; Sirota P
    Harefuah; 1996 May; 130(10):675-7, 727. PubMed ID: 8794656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients.
    Glazer WM; Ereshefsky L
    J Clin Psychiatry; 1996 Aug; 57(8):337-45. PubMed ID: 8752015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Maintenance electroconvulsive therapy and treatment of refractory schizophrenia].
    Lévy-Rueff M; Jurgens A; Lôo H; Olié JP; Amado I
    Encephale; 2008 Oct; 34(5):526-33. PubMed ID: 19068343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of subjective well-being in schizophrenic patients with gait parameters, expert-rated motor disturbances, and psychopathological status.
    Putzhammer A; Perfahl M; Pfeiff L; Hajak G
    Pharmacopsychiatry; 2005 May; 38(3):132-8. PubMed ID: 15902585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electroencephalography in schizophrenic patients: comparison between neuroleptic-naive state and after treatment.
    Nagase Y; Okubo Y; Toru M
    Biol Psychiatry; 1996 Sep; 40(6):452-6. PubMed ID: 8879464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.
    Nakamura M; Ogasa M; Guarino J; Phillips D; Severs J; Cucchiaro J; Loebel A
    J Clin Psychiatry; 2009 Jun; 70(6):829-36. PubMed ID: 19497249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.